大剂量肺栓塞中阿替普酶的剂量：是否应个体化？ - Suppr

Suppr

超能文献

The dose of alteplase in massive pulmonary embolism: should it be individualized?

作者信息

Garg Sunil Kumar

机构信息

Department of Critical Care, NMC Healthcare, Dubai, United Arab Emirates.

出版信息

Acute Crit Care. 2025 May;40(2):351-353. doi: 10.4266/acc.000850. Epub 2025 May 30.

DOI:10.4266/acc.000850

PMID:40494601

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12151745/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e786/12151745/3dec46434242/acc-000850f1.jpg

相似文献

The dose of alteplase in massive pulmonary embolism: should it be individualized?大剂量肺栓塞中阿替普酶的剂量：是否应个体化？

Acute Crit Care. 2025 May;40(2):351-353. doi: 10.4266/acc.000850. Epub 2025 May 30.

Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.双剂量瑞替普酶与阿替普酶静脉输注治疗大面积肺栓塞的血流动力学效应

Am Heart J. 1999 Jul;138(1 Pt 1):39-44. doi: 10.1016/s0002-8703(99)70243-7.

Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE.非免疫原性重组葡激酶与阿替普酶治疗大面积肺栓塞患者的疗效比较：一项随机开放标签、多中心、平行组、非劣效性试验，即FORPE试验

J Thromb Haemost. 2025 Feb;23(2):657-667. doi: 10.1016/j.jtha.2024.09.035. Epub 2024 Oct 23.

Successful Treatment of Refractory Massive Pulmonary Embolism with Repeated Administration of Systemic Thrombolysis.重复静脉溶栓成功治疗难治性大面积肺栓塞

Tanaffos. 2018 Feb;17(2):127-131.

Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up.链激酶与阿替普酶两小时治疗方案对急性大面积肺栓塞的疗效比较：即时临床和血流动力学结果及一年随访

J Am Coll Cardiol. 1998 Apr;31(5):1057-63. doi: 10.1016/s0735-1097(98)00068-0.

Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism.半剂量与全剂量阿替普酶治疗肺栓塞的比较。

Crit Care Med. 2018 Oct;46(10):1617-1625. doi: 10.1097/CCM.0000000000003288.

Tenecteplase Versus Alteplase: A Comparison of Bleeding Outcomes in Massive Pulmonary Embolism (TACO-PE).替奈普酶与阿替普酶对比：大面积肺栓塞出血结局的比较（TACO-PE研究）

Ann Pharmacother. 2025 Mar;59(3):232-237. doi: 10.1177/10600280241271264. Epub 2024 Aug 20.

Post-thrombolytic coagulopathy and complications in patients with pulmonary embolism treated with fixed-dose systemic alteplase.溶栓后凝血功能障碍与固定剂量全身性阿替普酶治疗肺栓塞患者的并发症。

J Thromb Thrombolysis. 2022 Nov;54(4):605-615. doi: 10.1007/s11239-022-02640-6. Epub 2022 Mar 23.

Multiple boluses of alteplase followed by extracorporeal membrane oxygenation for massive pulmonary embolism.多次注射阿替普酶联合体外膜肺氧合治疗大块肺栓塞。

Am J Emerg Med. 2019 Sep;37(9):1808.e5-1808.e6. doi: 10.1016/j.ajem.2019.06.029. Epub 2019 Jun 19.

Efficacy of thrombolytic agents in the treatment of pulmonary embolism.溶栓药物治疗肺栓塞的疗效

Eur Respir J. 2005 Nov;26(5):864-74. doi: 10.1183/09031936.05.00002505.

本文引用的文献

Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism.急性肺血栓栓塞症溶栓治疗的最新进展

Eurasian J Med. 2019 Jun;51(2):186-190. doi: 10.5152/eurasianjmed.2019.19291.

Low-Dose Systemic Alteplase (tPA) for the Treatment of Pulmonary Embolism.低剂量全身性组织型纤溶酶原激活剂（tPA）治疗肺栓塞

Ann Pharmacother. 2015 Jul;49(7):818-24. doi: 10.1177/1060028015579988. Epub 2015 Apr 9.

Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis.低剂量重组组织型纤溶酶原激活剂（rt-PA）治疗急性肺栓塞：系统评价和荟萃分析。

Thromb Res. 2014 Mar;133(3):357-63. doi: 10.1016/j.thromres.2013.12.026. Epub 2013 Dec 23.

Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.低剂量重组组织型纤溶酶原激活剂治疗急性肺血栓栓塞症的有效性和安全性：一项随机、多中心、对照试验。

Chest. 2010 Feb;137(2):254-62. doi: 10.1378/chest.09-0765. Epub 2009 Sep 9.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验